Prøve GULL - Gratis
India Announces Major Tax Cuts To Boost Investment
BioSpectrum Asia
|October 2019
In order to promote growth and investment in India, the Union Minister for Finance & Corporate Affairs Nirmala Sitharaman announced on September 20 that the Government of India has brought in the Taxation Laws (Amendment) Ordinance 2019 to make certain amendments in the Income-tax Act 1961 and the Finance (No. 2) Act 2019.
The Finance Minister at a press conference in Goa, a rare event to share such major decisions elaborated the salient features of these amendments. The minister said “a new provision has been inserted in the Incometax Act with effect from FY 2019-20 which allows any domestic company an option to pay income-tax at the rate of 22% subject to condition that they will not avail any exemption/incentive. The effective tax rate for these companies shall be 25.17% inclusive of surcharge & cess. Also, such companies shall not be required to pay Minimum Alternate Tax (MAT).”
She also noted that in order to attract fresh investment in manufacturing and thereby provide boost to ‘Make-in-India’ initiative of the government, another new provision has been inserted in the Income-tax Act with effect from FY 2019-20 which allows any new domestic company incorporated on or after October 1, 2019 making fresh investment in manufacturing, an option to pay income-tax at the rate of 15%. This benefit is available to companies which do not avail any exemption/incentive and commences their production on or before March 31, 2023. The effective tax rate for these companies shall be 17.01% inclusive of surcharge & cess. Also, such companies shall not be required to pay MAT.
The minister also said that a company which does not opt for the concessional tax regime and avails the tax exemption/ incentive shall continue to pay tax at the pre-amended rate. However, these companies can opt for the concessional tax regime after expiry of their tax holiday/exemption period. After the exercise of the option they shall be liable to pay tax at the rate of 22% and option once exercised cannot be subsequently withdrawn. Further, in order to provide relief to companies which continue to avail exemptions/incentives, the rate of MAT has been reduced from existing 18.5% to 15%.
Denne historien er fra October 2019-utgaven av BioSpectrum Asia.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA BioSpectrum Asia
BioSpectrum Asia
Waters launches charge detection mass spectrometry technology
US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia
The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
WHO strengthens coordination for NTD programmes and supply chain delivery
The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
All-in-one coronavirus vaccines to save millions in future pandemics
A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
NTU in Singapore introduces Master of Science course in Chinese Medicine
From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
ProSpecBio launches Activin-A recombinant protein for brain injury research
Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
PAHO publishes guide for designing AI instructions in public health
The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Prerna launches India's first MicroRNA based blood test for breast cancer screening
Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr
India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan
Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.
1 min
BioSpectrum Asia Nov 2025
Translate
Change font size

